Germany-based clinical stage biotech company Immunic Therapeutics has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) to start a Phase ll trial of IMU-838 in patients with ulcerative colitis (UC).

The CALDOSE-1 trial is intended to help Immunic eventually demonstrate clinical efficacy of IMU-838 for the treatment of inflammatory bowel disease (IBD).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

CALDOSE-1 aims to evaluate the efficacy of multiple doses of IMU-838 or placebo to induce symptomatic and endoscopic remission in patients with active UC.

It is expected to be conducted in the early part of this year across multiple sites in the US and Europe.

“This step underlines that we’re progressing well on our way to deliver a phase III ready product in due time.”

Immunic Therapeutics CEO Dr Daniel Vitt said: “This step underlines that we’re progressing well on our way to deliver a phase III ready product in due time.”

The company is also planning to start second Phase ll trial, CALDOSE-2, to treat patients with Crohn’s disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The proposed trial is expected to begin after receiving interim data from the new Phase ll trial of UC.

Immunic’s MU-838 is an orally available, next-generation selective immune modulator that targets intracellular metabolism of activated immune cells by inhibition of the enzyme ‘dihydroorotate dehydrogenase’ (DHODH).

IMU-838 was previously tested for pharmacokinetics (PK) and safety in two Phase ll studies.